BBOT to Participate in Upcoming Investor Healthcare Conferences

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will participate in two investor healthcare conferences in Feb–Mar 2026.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will participate in two investor healthcare conferences in Feb–Mar 2026.

Presentations: Oppenheimer on Feb 25, 2026 at 10:40 a.m. ET and Leerink on Mar 10, 2026 at 10:00 a.m. ET. Live webcasts will be available on BBOT's Events page and replays will be accessible for at least 90 days.

Argus Feb 13 session

-1.49% close to close Open Argus

Details

News Market Reaction – BBOT

On Feb 13, the first trading day after this news, BBOT closed 1.49% below the previous close.

Data tracked by StockTitan Argus for the Feb 13 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months.

Details of the company’s participation are as follows:

• Oppenheimer 36th Annual Healthcare Life Sciences Conference
  Presentation: Wednesday, February 25, 2026, at 10:40 a.m. ET.
  

• Leerink Global Healthcare Conference
  Presentation: Tuesday, March 10, 2026, at 10:00 a.m. ET.
  
  

Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong
BBOT
Heather.Armstrong@bbotx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will BBOT present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (BBOT)?

BBOT will present at Oppenheimer on Wednesday, February 25, 2026 at 10:40 a.m. ET in a live investor presentation. According to the company, the session will be webcast live and a replay will be posted on BBOT's Events page for at least 90 days.

When is BBOT scheduled to present at the Leerink Global Healthcare Conference (BBOT)?

BBOT is scheduled to present at Leerink on Tuesday, March 10, 2026 at 10:00 a.m. ET as part of the conference agenda. According to the company, the presentation will be webcast and replays will remain available on the Events page for at least 90 days.

How can investors watch BBOT's February–March 2026 investor presentations and how long are replays available?

Investors can watch live webcasts on BBOT's Events page; replays are available for at least 90 days after each event. According to the company, links to the live streams and on-demand replays will be posted at https://investors.bbotx.com/news-events/events.

What topics will BBOT likely cover during its Feb–Mar 2026 conference presentations (BBOT)?

BBOT indicated leadership will participate at the conferences but did not provide a detailed agenda in the notice. According to the company, investors should view the live webcast or replay for specific slide decks, clinical updates, and management remarks.